share_log

Insulet | 10-Q: Q3 2024 Earnings Report

Insulet | 10-Q: Q3 2024 Earnings Report

银休特 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/09 02:26

Moomoo AI 已提取核心信息

Insulet Corporation reported strong financial results for Q3 2024, with total revenue increasing 25.7% to $543.9 million, driven by robust Omnipod sales growth. U.S. Omnipod revenue rose 23.4% to $395.6 million, while International Omnipod revenue jumped 36.1% to $138.0 million. Net income grew 49.3% to $77.5 million, with gross margin improving to 69.3% from 67.8% year-over-year.The company achieved significant operational milestones, including the launch of Omnipod 5 with Dexcom's G7 CGM in the U.S. and expansion of Omnipod 5 availability in European markets. Production began at the new Malaysia manufacturing facility, which is expected to drive higher gross margins over time. The company also received FDA clearance for Omnipod 5 use in type 2 diabetes patients.Looking ahead, Insulet expects continued strong revenue growth driven by Omnipod 5 adoption and international expansion. The company maintains a solid financial position with $902.6 million in cash and cash equivalents. Management anticipates full-year 2024 gross margin to be approximately 69%, supported by higher average selling prices and improved manufacturing efficiencies.
Insulet Corporation reported strong financial results for Q3 2024, with total revenue increasing 25.7% to $543.9 million, driven by robust Omnipod sales growth. U.S. Omnipod revenue rose 23.4% to $395.6 million, while International Omnipod revenue jumped 36.1% to $138.0 million. Net income grew 49.3% to $77.5 million, with gross margin improving to 69.3% from 67.8% year-over-year.The company achieved significant operational milestones, including the launch of Omnipod 5 with Dexcom's G7 CGM in the U.S. and expansion of Omnipod 5 availability in European markets. Production began at the new Malaysia manufacturing facility, which is expected to drive higher gross margins over time. The company also received FDA clearance for Omnipod 5 use in type 2 diabetes patients.Looking ahead, Insulet expects continued strong revenue growth driven by Omnipod 5 adoption and international expansion. The company maintains a solid financial position with $902.6 million in cash and cash equivalents. Management anticipates full-year 2024 gross margin to be approximately 69%, supported by higher average selling prices and improved manufacturing efficiencies.
银休特公司报告了2024年第三季度强劲的财务业绩，总营业收入增加了25.7%，达到54390万美元，主要受益于Omnipod销售增长。美国Omnipod营业收入增长了23.4%，达到39560万美元，而国际Omnipod营业收入猛增36.1%，达到13800万美元。净利润增长了49.3%，达到7750万美元，毛利率从67.8%提高到69.3%。该公司实现了显著的运营里程碑，包括在美国推出与德康医疗的G7 CGM兼容的Omnipod 5，并扩大了Omnipod 5在欧洲市场的可用性。新建的马来西亚制造业-半导体工厂已开始生产，预计将随着时间的推移推动更高的毛利率。该公司还获得了FDA批准，允许在...展开全部
银休特公司报告了2024年第三季度强劲的财务业绩，总营业收入增加了25.7%，达到54390万美元，主要受益于Omnipod销售增长。美国Omnipod营业收入增长了23.4%，达到39560万美元，而国际Omnipod营业收入猛增36.1%，达到13800万美元。净利润增长了49.3%，达到7750万美元，毛利率从67.8%提高到69.3%。该公司实现了显著的运营里程碑，包括在美国推出与德康医疗的G7 CGM兼容的Omnipod 5，并扩大了Omnipod 5在欧洲市场的可用性。新建的马来西亚制造业-半导体工厂已开始生产，预计将随着时间的推移推动更高的毛利率。该公司还获得了FDA批准，允许在2型糖尿病患者中使用Omnipod 5。展望未来，银休特预计Omnipod 5的采纳和国际扩展将推动持续强劲的营业收入增长。该公司保持稳健的财务状况，现金及现金等价物达到90260万美元。管理层预计2024年全年毛利率将约为69%，并将受益于更高的平均售价和改善的制造效率。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日